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INTRODUCTION
Immunotherapy targeting B-cell antigens continues to play a central role in treating nonHodgkin lymphoma (NHL). Since anti-CD20 antibodies by themselves achieve low rates of complete responses, they are often combined with chemotherapy or given afterwards as maintenance therapy. [1] [2] [3] [4] [5] However, radiolabeled anti-CD20 antibodies are more potent, with a single course of radioimmunotherapy capable of generating substantially higher response rates, including complete responses. [6] [7] [8] [9] [10] CD22 is another B-cell antigen expressed across most NHL histologies. CD22 also internalizes rapidly into the cell after binding with epratuzumab, a humanized anti-CD22 antibody which also has therapeutic activity. [11] [12] [13] [14] [15] [16] [17] For radioimmunotherapy, enhanced delivery and retention of the radioisotope at tumor sites should further improve outcome, so epratuzumab was conjugated with DOTA (1,4,7,10-tetraazacyclododecane-N,N′,N′',N -tetraacetic acid), an improved chelator for 90-yttrium ( 90 Y) binding. 18 The resulting radiolabeled antibody, 90 Y-epratuzumab tetraxetan, was well tolerated and active in initial studies in relapsed/refractory NHL. 19, 20 Following theoretical considerations, 21 90 Y-epratuzumab tetraxetan was then administered in fractionated doses once-weekly for 2-3 consecutive weeks, allowing delivery of higher cumulative doses with favorable response rates compared to anti-CD20 radioimmunotherapy with 90 Y-ibritumomab tiuxetan or 131 Itositumomab. 22 Combining immunotherapy with the more potent radioimmunotherapy is also an attractive prospect for NHL. 90 Y-ibritumomab tiuxetan and 131 I-tositumomab are both administered with additional anti-CD20 antibody (~900 mg). This cold anti-CD20
antibody prevents sequestration of the radiolabeled anti-CD20 antibody by the normal B-cell antigen sink for improved biodistribution, [23] [24] [25] but could also act competitively to reduce uptake of the more potent radiolabeled antibody at tumor sites of malignant B lymphocytes. 26, 27 Since CD20 and CD22 are distinct antigens on B-cells, the possibility of blocking tumor uptake would be eliminated if 90 Y-epratuzumab tetraxetan were used instead. In this case, cold anti-CD20 antibody could then potentially be given at singleagent dose levels for full therapeutic effects on its own. 28 Based on the above considerations, we combined 90 Y-epratuzumab tetraxetan with veltuzumab, a humanized anti-CD20 antibody with structure-function differences from rituximab. 29, 30 In NHL clinical trials, veltuzumab demonstrated single-agent activity comparable to rituximab even at low doses. 31, 32 Preclinical studies showed 90 Yepratuzumab tetraxetan with veltuzumab substantially improved therapeutic responses compared to either agent alone. 33 As such, we hypothesized that both agents could be combined clinically for maximum therapeutic benefit without interfering with tumor targeting or increasing toxicity over that reported previously when given separately. 
METHODS
Adults with aggressive B-cell NHL who failed ≥1 standard chemotherapy regimen were eligible if they had at least one lesion >1.5 cm by CT (but none >10 cm), ECOG 0-1, hemoglobin ≥ 10 g/dL, neutrophils ≥ 1.5 × 10 9 /L, platelets ≥ 100 × 10 9 /L, serum creatinine and bilirubin ≤ 1. In the absence of DLT or HAHA, retreatment was allowed at the discretion of the investigator any time after hematologic toxicity had recovered to Grade 1 levels. The institutional review board at each site approved the study, with written informed consent obtained from all patients.
RESULTS
A total of 18 patients were enrolled between October 2010 and October 2012. They met all protocol entry criteria except for 3 waivers granted for oral antibiotics (asymptomatic urinary tract infection), prior radioimmunotherapy 5 years earlier (patient met bone marrow requirements), and <10 g/dL hemoglobin (9.7 g/dL in patient with stable chronic anemia). Demographics and baseline characteristics are summarized in Table 1 .
Treatment
All 18 patients completed their scheduled treatment doses. Three patients had brief interruptions (5 -30 minutes) of veltuzumab infusions for mild-moderate reactions that resolved spontaneously (mild itching, chills) or with IV steroids (pruritis/hives).
Veltuzumab infusion times were a median (range) of 2.0 (1.1 -2.9), 1. 
Adverse Events
Five patients had serious adverse events (SAEs). Two patients ( Treatment-related events occurred in 15 (83%) of the 18 patients; except for cytopenias which are a known consequence of radioimmunotheapy and the 2 SAEs of pneumonitis/atypical pneumonia, these were all Grade 1-2 events with only fatigue, nausea and anorexia occurring in more than one patient. 
Treatment Response
Treatment response assessments used revised criteria, 36 incorporating results from CT imaging as well as additional FDG-PET studies conducted in 6 patients. One patient withdrew early after developing pneumonia-like symptoms and was unable to be assessed for response. At first evaluation 4 weeks after treatment, the other 17 patients improving to CR (Figure 1) . Based on best response, the overall objective response (OR=CR+PR) rate was 53% (9/17) and the CR rate was 18% (3/17), with 4 other patients (24%) achieving SD. 
Laboratories
Blood counts obtained at least weekly showed dose-dependent thrombocytopenia and neutropenia with little anemia following treatment ( Table 2) . Platelet and neutrophil levels started declining by the second dose of 90 Y-epratuzumab tetraxetan, with nadirs occurring 3-5 weeks after treatment for platelets and 4-7 weeks for neutrophils.
Platelet and neutrophil counts then generally improved to Grade 1 levels over several weeks and reached normal levels by 9-12 weeks after treatment. Serum chemistries evaluated last treatment day, then 4 or 12 weeks later, showed no evidence of renal or liver abnormalities (Table S- 3, online supplement) .
At study entry, B-cell blood levels were variable, including 5 patients with levels too low to be measured. As shown in Figure 3 
Immunogenicity (HAHA)
Serum samples at baseline, 4 and 12 weeks after treatment were negative (<50 ng/mL) for both anti-epratuzumab and anti-veltuzumab antibodies, except one sample at 12 weeks, which was borderline positive only for anti-veltuzumab antibodies (60 ng/mL).
Epratuzumab Doses
Following prior studies of 90 older than the prior study of 90 Y-epratuzumab tetraxetan alone, 22 with a median age of 73 vs. 64, respectively. In addition, they were more heavily pretreated with a median of 3 prior treatment regimens for aggressive disease, compared to 2 regimens in the prior study of 90 Y-epratuzumab tetraxetan alone which was primarily for indolent disease, and only one regimen in the consolidation study. 39 Thus, the population here may not have been able to tolerate the same dose of 90 Y-epratzumab tetraxetan as given previously alone due to the increased bone marrow damage sustained from the more intensive prior chemotherapy they had received. Finally, a more conservative hematologic DLT definition was used here, in which the occurrence of Grade 4 cytopenias > 7 days was considered DLT instead of related clinical events (bleeding due to thrombocytopenia, neutropenic fever/infection) as had been done previously. 22 This more stringent definition may also have contributed to the lower dose determined to be acceptable in this study. CRs. Thus, this treatment regimen appears active in these populations, and further study of this combination approach in aggressive lymphoma appears warranted.
DISCUSSION
Prior studies of radioimmunotherapy with 90 Y-epratzumab tetraxetan alone also administered unlabeled epratuzumab to prevent potential sequestration of the radiolabeled antibody by the B-cell pool in the spleen, blood or bone marrow.
Interestingly, even with the addition of veltuzumab in this regimen, the same small dose of added epratuzumab received by the initial 7 patients still had an apparent measurable effect on splenic uptake and serum circulation of the 111 In-epratzumab tetraxetan. However, these findings are of questionable clinical significance, and since there was no apparent difference seen in tumor targeting, the added epratuzumab was discontinued as being unnecessary with this combination approach. Both veltuzumab and epratuzumab are therapeutically active, so the efficacy observed in this study may be partly due to the "naked" antibody administered. Finally, two patients were retreated at investigator discretion with no additional safety concerns: one with a PR after initial treatment converting into a CR with retreatment, the other after initially relapsing following a CR, achieving a PR with 2 additional retreatments. Since both epratuzumab and veltuzumab are humanized antibodies, the expected lack of significant immunogenicity should allow not only repeated treatment cycles of combination therapy to be given, but extended maintenance dosing afterwards. These considerations remain areas for further exploration.
In conclusion, this combination approach has a sound rationale, addressing historical critiques of radioimmunotherapy regimens giving 'cold' antibody targeting the same antigen as the 'hot' antibody, and uses improved 90 Y chelation and a fractionated dosing schedule intended for better delivery and retention of the radioisotope at the tumor sites.
This regimen would be well suited for the elderly or other patients with aggressive disease who relapse and are not candidates for stem-cell transplant, and would also be ideal to combine with an oral agent such as ibrutinib, everolimus or lenalidomide.
Whether this combination approach truly represents an advance over currently approved radioimmunotherapy regimens remains to be determined in a controlled setting. However, we observed encouraging therapeutic activity in difficult-to-treat patients with relapsed/refractory aggressive NHL and an acceptable 90 Y dose was determined for further studies. A phase 2 study is now in progress comparing the combination to a control arm receiving only 90 Y-epratuzumab tetraxetan. 
